ArticleBMJ open2022

Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn's disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study.

Emma Paulides et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.